XATOC – Xarelto + Acetylsalicylic Acid
abstract |
Treatment patterns and Outcomes across the disease
Continuum in patterns and decision points for treatment in patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) treated with rivaroxaban 2.5 mg [twice a day (BID)] plus low-dose ASA (75-100 mg) [once a day (OD)] for the prevention of atherothrombotic events in adult patients at high risk of ischemic events, and to describe the outcomes under this combination across the broad range of patient risk profiles encountered in routine clinical practice |
type of project | clinical studies |
status | ongoing - follow up |
start of project | 2020 |
study design | Observational |
responsible person | Prof. Dr. med. Hans Rickli |